Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on December 30, 2021, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Monmouth Junction, New Jersey. Its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
As of the end of the third quarter of 2021, the company reported the following liquidity position:
- Cash Balance: Approximately $61.0 million.
- Debt: No debt.
The filing does not provide specific values for revenue, profit, cash flow, or margins for the reporting period.
Material Changes and Agreements
On December 30, 2021, the company entered into an Open Market Sale Agreement with Jefferies LLC. Key terms include:
- Offering Type: "At the market" offering of common stock.
- Capacity: Up to $25,000,000 of shares under a previously effective Form S-3 registration statement.
- Commission: Jefferies LLC will receive a commission of 3.0% of gross proceeds from any sales.
- Intent: The company stated it does not intend to immediately sell shares under this agreement but views it as a measure for long-term financing flexibility.
Outlook, Risks, and Management Commentary
Management characterized the agreement as a matter of good corporate governance to enhance financing strategy flexibility. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ from projections due to risks and uncertainties. No specific operational guidance or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the current cash balance and burn rate relative to the $61.0 million reported for Q3 2021.
- Monitor future filings for actual share issuances and proceeds generated under the Jefferies LLC agreement.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination clauses or conditions.
- Confirm the status of the Form S-3 registration statement (File No. 333-257910) for any amendments or expirations.